Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06476808 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC), sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
240
Enrollment target
16
Study locations

NCT06476808 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 240 participants, below the 285-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (16% lower). The trial reports 16 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06476808, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and High-grade Serous Ovarian Carcinoma (HGSOC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
240 participants
Enrollment target
16
Study locations

Study Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

Conditions Studied

Non-small Cell Lung Cancer (NSCLC) High-grade Serous Ovarian Carcinoma (HGSOC) Uterine Serous Carcinoma (USC)

Interventions

  • DRUG BMS-986463

Study Locations (16)

Other

  • Local Institution - 0036 - Borddeaux Cedex
  • Local Institution - 0035 - Lyon
  • Local Institution - 0033 - Milan
  • Local Institution - 0041 - Avda.Pio XII 36,
  • Local Institution - 0042 - Barcelona

California

  • USC/Norris Comprehensive Cancer Center - Los Angeles
  • Valkyrie Clinical Trials - Los Angeles

Quebec

  • Centre Hospitalier de l'Université de Montréal - Montreal
  • Jewish General Hospital - Montreal

New Jersey

  • John Theurer Cancer Center at Hackensack University Medical Center - Hackensack

Ohio

  • Local Institution - 0045 - Columbus

Texas

  • Local Institution - 0046 - Dallas

British Columbia

  • BC Cancer Vancouver - Vancouver

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2024-09-06
Est. Completion 2028-12-19
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06476808

The ClinicalTrials.gov registry entry for NCT06476808 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (16% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention - of which BMS-986463 is the first listed.

NCT06476808 reports 16 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Quebec.

Frequently Asked Questions

What is clinical trial NCT06476808 about?

NCT06476808 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.". The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

What is the current status of trial NCT06476808?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 240 participants. The study started on 2024-09-06. Estimated completion is 2028-12-19.

What conditions does trial NCT06476808 study?

This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC).

What interventions are being tested in trial NCT06476808?

The interventions under investigation include: BMS-986463 (DRUG).

Who is sponsoring clinical trial NCT06476808?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06476808 being conducted?

This trial has 16 study locations across California, New Jersey, Ohio, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-small Cell Lung Cancer (NSCLC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-small Cell Lung Cancer (NSCLC)

All registered trials for this condition

High-grade Serous Ovarian Carcinoma (HGSOC)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.